



PRESS RELEASE
FOR IMMEDIATE RELEASE

KDA GROUP CLOSSES DEBENTURE AND ANNOUNCES WEBINAR TO DISCUSS CORPORATE UPDATE

Thetford Mines, Quebec – June 23, 2021 – KDA Group Inc. (TSXV: KDA) (“**KDA**” or the “**Corporation**”) is pleased to announce the closing of an unsecured convertible debenture in the amount of \$750,000 at a ten percent (10%) interest rate per year for a term of two (2) years (the “**Debenture**”) with an accredited investor. The Debenture is convertible at the choice of the Debenture holder for up to 5,000,000 Class A share (“**Common Share**”) in the share capital of KDA at a conversion price of \$0.15 per Common Share for a period of 24 months following the closing of the Debenture.

The Corporation may, at any time after the issuance of the Debenture, redeem the Debenture, in whole or in part, and in any case where the Corporation notifies the Debenture holder of its intention to redeem the Debenture, the Debenture holder shall have the right, at its option, to convert the Debenture by notifying the Corporation.

KDA will use the Debenture proceeds for its working capital and general corporate purposes.

No finder’s fee and commission are payable in connection with the Debenture.

The Debenture is subject to final acceptance by the TSX Venture Exchange.

WEBINAR

The Corporation will host a corporate update webinar on Wednesday, August 4, 2021 at 10:00 a.m. EDT, that will provide shareholders and investors with an update on the Corporation’s recent business developments.

Specifically, the webinar will feature KDA’s Chairman, Marc Lemieux; Chief Executive Officer, Sylvain Duvernay; and Chief Financial Officer, Pierre Monet, to discuss corporate update and answer questions from participants.

Participants can register at the following address:

<https://attendeegotowebinar.com/register/427124399329661964>

ABOUT KDA GROUP

KDA Group is a leading technological innovations and specialized solutions provider in the pharmaceutical market. Today, it is a respected name for quality and expertise among the different stakeholders in the pharmaceutical and medical sector. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

INFORMATION

Sylvain Duvernay
Chief Executive Officer
514 622-7370
info@groupekda.ca